Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer

Anticancer Research

Volumn 22, Issue 6 B, 2002, Pages 3789-3792

  Saeki, Hiroshi ^a   Ito, Shuhei ^a   Futatsugi, Motonori ^a   Kimura, Yasue ^a   Ohga, Takefumi ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

5 FU; DPD activity; Esophageal squamous cell carcinoma; Peripheral blood mononuclear cells; Side effects

Indexed keywords

CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DIARRHEA; ENZYME ACTIVITY; ESOPHAGUS CANCER; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MONONUCLEAR CELL; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DIHYDROURACIL DEHYDROGENASE (NADP); DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OXIDOREDUCTASES;

EID: 0036875153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sugimachi K: Advances in the surgical treatment of oesophageal cancer. Br J Surg 85: 289-290, 1998.
2. Okuma T, Yoshioka M, Isechi S, Kondo K, Tabira Y, Torigoe Y and Miyauchi Y: Preoperative chemotherapy for esophageal cancer based on chemosensitivity testing. J Thorac Cardiovasc Surg 108: 823-829, 1994.
3. Adelstein DJ, Rice TW, Becker M, Larto MA, Kirby TJ, Koka A, Tefft M and Zuccaro G: Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 80: 1011-1020, 1997.
4. Diasio RB and Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinetic 16: 215-237, 1989.
5. Diasio RB and Lu Z: Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 12: 2239-2242, 1994.
6. Tuchman M, Stoeckeler JS, Kiang DT, O'Dea RF, Ramnaraine ML and Mirkin BL: Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313: 245-249, 1985.
7. Diasio RB, Beavers TL and Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81: 47-51, 1988.
8. Milano G and Etienne MC: Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil. Anticancer Res 14: 2295-2297, 1994.
9. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N and Milano G: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 10: 1517-1522, 1994.
10. Etienne MC, Cheradame S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
11. Sugimachi K, Matsuda H, Ohno S, Fukuda A, Matsuoka H, Mori M and Kuwano H: Long-term effects of hyperthermia combined with chemotherapy and irradiation for the treatment of patients with carcinoma of the esophagus. Surg Gynecol Obstet 167: 319-323, 1988.
12. Sugimachi K, Kuwano H, Ide H, Toge T, Saku M and Oshiumi Y: Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective randomized trial. Int J Hyperthermia 10: 485-493, 1994.
13. Saeki H, Kawaguchi H, Kitamura K, Ohno S and Sugimachi K: Recent advances in preoperative hyperthermochemoradiotherapy for patients with esophageal cancer. J Surg Oncol 69: 224-229, 1998.
14. Japanese Society for Esophageal Diseases: Guideline for the clinical and pathological studies on carcinoma of the esophagus. Jpn J Surg 6: 79-86, 1976.
15. Harris BE, Song R, Soong SJ and Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990.
16. Grem JL, Yee LK, Venzon DJ, Takimoto CH and Allegra CJ: Inter-and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 40: 117-125, 1997.
17. Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM and Tattersall MH: On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19: 203-208, 1983.
18. Tsavaris N, Tentas K, Bacoyiannis C, Katsikas M, Sakelaropoulos N, Kosmas C, Daliani D and Kosmidis P: 5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study. Anti Cancer Drugs 6: 599-603, 1995.
19. Morita M, Kuwano H, Ohno S, Kitamura K and Sugimachi K: Antiemetic effect of ramosetron during hyperthermo-chemoradiotherapy for esophageal cancer. Anticancer Res 20: 3631-3636, 2000.
20. Ohno S, Siddik ZH, Baba H, Stephens LC, Strebel FR, Wondergem J, Khokhar AR and Bull JM: Effect of carboplatin combined with whole body hyperthermia on normal tissue and tumor in rats. Cancer Res 51: 2994-3000, 1991.
21. Zhang R, Lu Z, Liu T, Soong SJ and Diasio RB: Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res 53: 2816-2822, 1993.
22. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M and Demard F: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899-2902, 1992.
23. Chazal M, Etienne MC, Renee N, Bourgeon A, Richelme H and Milano G: Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 2: 507-510, 1996.
24. Lu Z, Zhang R and Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433-5438, 1993.